A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
M. D. Green, Heinz Koelbl, José Baselga et al. · Annals of Oncology · 2002
Cited by 586 works. doi:10.1093/annonc/mdg019
Authors
- M. D. Green
- Heinz Koelbl
- José Baselga
- A. Galid
- Vicente Guillém
- Pere Gascón
- Salvatore Siena
- Roy Iqbal Lalisang
- H. Samonigg
- Michael Clemens
- V. Zani
- Bertrand C. Liang
- J Renwick
- Martine J Piccart
References
- Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia
- Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
- EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY
- Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
- Filgrastim (r-metHuG-CSF): the first 10 years
- The uses and properties of PEG-linked proteins.
- Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer
- Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor
- Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving Chemotherapy